Dr. John Cush RheumNow
1 year 4 months ago
CDC: U.S. Overdose Deaths Decrease Almost 27% in 2024, dropping from 110,037 deaths (2023) to ~80,391(2024). Despite these improvements, overdose remains the leading cause of death for Americans aged 18 to 44. https://t.co/UXTaOPf3P7 https://t.co/1NQUfoZ1eK
Dr. John Cush RheumNow
1 year 4 months ago
Single center study of 2741 ANA tests: 65% ANA negative, 31% ANA+ w/ nuclear staining patterns, & 2.0% ANA+ w cytoplasmic staining. Cytoplasmic - most were reticular, dense fine speckled next. Reticular assoc w/ primary biliary cholangitis (w/ Abs against M2). Dense fine https://t.co/JI7iGvw8xp
Dr. John Cush RheumNow
1 year 4 months ago
QD Clinic - Refractory Renal SLE
How to manage class III/IV lupus glomerulonephritis when you run out of options
Features Dr. Jack Cush.
https://t.co/8CQm8GZ213 https://t.co/lJKvcpIq60
Dr. John Cush RheumNow
1 year 4 months ago
QOL survey of on 5222 lupus pts (94% F; 56% both CLE/SLE; 40% w/ SLE. QOL concerns on social activities (60%), mental health (38%). CLE had increased therapeutic hesitancy and less likely to believe in the efficacy of biologics than SLE or both. https://t.co/BOUXUSmmcM https://t.co/62Z1aFsbbv
Dr. John Cush RheumNow
1 year 4 months ago
#2 most downloaded paper in 2024 on Journal of Clinical Medicine was “IgA Vasculitis (Henoch–Schönlein Purpura): An Update on Treatment” - Steroids are 1st line Rx, esp in adults w/ severe IgAV; other Rx include calcineurin inhibitors, MMF, RTX , https://t.co/F5jogxkoGr
Dr. John Cush RheumNow
1 year 4 months ago
National Inpatient Sample retrospective study of #RA pts using cannabis (n 42,415). Cannabis assoc w/ lower mortality (0.98% vs 2.71%; OR 0.50), depression (OR 0.47), chronic pain (OR 0.45), anxiety (OR 0.55); but more use of opioids (OR: 1.10), nicotine (OR: 1.35), & alcohol https://t.co/87SnCHVxkN
Dr. John Cush RheumNow
1 year 4 months ago
Is the nosology of CPPD outdated? Pseudogout to chondrocalcinosis? In 2011 EULAR taskforce rec the preferred term "calcium pyrophosphate deposition dz". G-CAN aims to update & standardised terminology for CPPD, requiring change to ICD-10 & adoption by societies https://t.co/mdqwDQN1po
Dr. John Cush RheumNow
1 year 4 months ago
Soluble CD13 (sCD13) has pro-inflammatory effects & is elevated in severe COVID-19. sCD13 is chemotactic, angiogenic, & arthritogenic. In COVID-19, sCD13 was assoc w/ sCD13 severity, ethnicity, inflammation markers, NETosis, & vascular injury/thrombosis. https://t.co/2bKY9NtnCD
Dr. John Cush RheumNow
1 year 4 months ago
Comparing EULAR (2025) and ACR (2020) Guidelines on Safety of Lupus Medications in Pregnancy Attendees at the 2025 RheumaPreg meeting were excited to discuss the newly released EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation. https://t.co/DSYPaElRij
Dr. John Cush RheumNow
1 year 4 months ago
Retrospective cohort study 112 biopsy-proven Lupus nephritis pts (65% class IV; F/U 8.3 yrs). (64.3%), alone or in combination. Renal damage incr betw 5 & 10 yrs F/U. 13.4% progressed to renal function impairment, and 11.6% to ESRD. Early Dx & Rx of LN, esp w/ highproteinuria, https://t.co/yHzN1Hczb4
Dr. John Cush RheumNow
1 year 4 months ago
A brief history of familial Mediterranean fever - FMF is most common periodic fever syndr. an inherited polyserositis mainly affects Arabs, Armenians, Jews, & Turks. Hx may date back to 1802 & Heberden. Osler described 11 cases in 1895. 1st clear report 1945 by Siegal 10 pts. https://t.co/61WOxt9fPy
Dr. John Cush RheumNow
1 year 4 months ago
QOL survey of on 5222 lupus pts (94% F; 56% both CLE/SLE; 40% w/ SLE. QOL concerns on social activities (60%), mental health (38%). CLE had increased therapeutic hesitancy and less likely to believe in the efficacy of biologics than SLE or both. https://t.co/BOUXUSmmcM https://t.co/zrzEsDDqVn
Dr. John Cush RheumNow
1 year 4 months ago
#2 most downloaded paper in 2024 on Journal of Clinical Medicine was “IgA Vasculitis (Henoch–Schönlein Purpura): An Update on Treatment” - Steroids are 1st line Rx, esp in adults w/ severe IgAV; other Rx include calcineurin inhibitors, MMF, RTX , https://t.co/F5jogxkoGr
We’ve recognized the increased risk of cardiovascular disease (CVD) in SLE for almost half a century since Urowitz et al. first described a bimodal pattern of mortality in lupus patients in 1976. Numerous subsequent studies have confirmed this, with estimates of increased risk ranging from 2-10-fold compared to the general population. Most striking is the risk in young patients; in their landmark study, Manzi et al. found that women with
